proQura

The industry solution for the implementation of KVG Art. 56 3bis and VITH for outpatient specialists

Since 1 January 2020, new legal provisions have applied to the handling of discounts on medicinal products. According to Art. 56 para. 3bis KVG and the Ordinance on Integrity and Transparency in the Therapeutic Products Sector (VITH) ), doctors must pass on at least 51% of the rebates to the health insurers. They can retain up to a maximum of 49% of the rebates received if they can prove that they are using these rebates to improve the quality of treatment. The details are regulated in the national contract between FMH and health insurers. proQura is fully integrated into the national contract and has established itself as an industry solution for implementing the VITH. proQura is aimed at outpatient specialists and supports them in implementing the new provisions in accordance with the law. proQura is our own development and aims to make an important contribution to increasing quality and reducing costs in the healthcare system.

The proQura range includes

  • We conclude contracts with health insurers and pharmaceutical companies that regulate the receipt and passing on of discounts.
  • Specialists have access to a wide range of discounts on therapeutic products, with a focus on off-patent originals, biosimilars and generics.
  • The specialists plan and document their quality measures using the proQura quality catalogue. This is continuously updated in collaboration with medical associations. All quality measures are based on scientific evidence. The quality catalogue is subject to an annual external evaluation.
  • We settle the discounts among the proQura participants (specialists, health insurers and pharmaceutical companies).
  • We support the participating specialists in fulfilling their accountability obligations with regard to drug discounts to the FMH, health insurers and the FOPH.

The following pharmaceutical companies currently grant discounts via proQura: Accord, Amgen, AstraZeneca, Bayer, Biogen, Daiichi Sankyo, Devatis, iQone, Janssen-Cilag, Labatec, Mepha, Nordic, Octapharma, Pfizer, Roche, Sandoz, Spirig HC, Takeda, Viatris, Zentiva